Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
13 Nov 2024
// BUSINESSWIRE
12 Nov 2024
// BUSINESSWIRE
04 Nov 2024
// BUSINESSWIRE
22 Oct 2024
// FIERCE PHARMA
https://www.fiercepharma.com/marketing/savara-sponsors-lifetime-talk-show-episode-about-rare-respiratory-disease-ahead-fda
22 Oct 2024
// BUSINESSWIRE
18 Oct 2024
// BUSINESSWIRE
Details:
Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2024
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Launches Expanded Access Program For Molgramostim in aPAP Patients
Details : Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 27, 2024
Details:
The net proceeds will be used to fund the clinical development and approval of molgramostim, which is being evaluated in the treatment of autoimmune pulmonary alveolar proteinosis.
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: Molgradex
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Jefferies
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2024
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $100.0 million
Deal Type : Public Offering
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Details : The net proceeds will be used to fund the clinical development and approval of molgramostim, which is being evaluated in the treatment of autoimmune pulmonary alveolar proteinosis.
Brand Name : Molgradex
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 28, 2024
Details:
Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Reports Molgramostim Achieved Significance in Phase 3 IMPALA-2 Trial for aPAP
Details : Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
The net proceeds will be used for the development of molgramostim nebulizer solution, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Lead Product(s): Molgramostim
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Jefferies
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 13, 2023
Lead Product(s) : Molgramostim
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $80.0 million
Deal Type : Public Offering
Details : The net proceeds will be used for the development of molgramostim nebulizer solution, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 13, 2023
Details:
Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 26, 2023
Details:
Data demonstrated that patients treated with molgramostim after undergoing WLL had greater improvements in endpoint measures of gas exchange, including alveolar-arterial oxygen difference and diffusing capacity of the lungs for carbon monoxide corrected for hemoglobin levels.
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
Details : Data demonstrated that patients treated with molgramostim after undergoing WLL had greater improvements in endpoint measures of gas exchange, including alveolar-arterial oxygen difference and diffusing capacity of the lungs for carbon monoxide corrected ...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 06, 2022
Details:
Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: Molgramostim
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Molgramostim is delivered via an investigational eFlow® Nebulizer System. Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP...
Brand Name : Molgramostim
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 20, 2022
Details:
Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH).
Lead Product(s): Molgramostim
Therapeutic Area: Rare Diseases and Disorders Brand Name: rhGM-CSF
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Silicon Valley Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2022
Lead Product(s) : Molgramostim
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Silicon Valley Bank
Deal Size : Undisclosed
Deal Type : Financing
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
Details : Molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer Syste...
Brand Name : rhGM-CSF
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 22, 2022
Details:
The Company announced that the Phase 3 trial of AeroVanc (vancomycin hydrochloride inhalation powder) in people living with cystic fibrosis (CF) who have Methicillin-resistant Staphylococcus aureus (MRSA) lung infection did not meet the primary endpoint.
Lead Product(s): Vancomycin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: AeroVanc
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Savara Provides Pipeline and Business Update
Details : The Company announced that the Phase 3 trial of AeroVanc (vancomycin hydrochloride inhalation powder) in people living with cystic fibrosis (CF) who have Methicillin-resistant Staphylococcus aureus (MRSA) lung infection did not meet the primary endpoint.
Brand Name : AeroVanc
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2020
Details:
Company has decided to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF).
Lead Product(s): Molgramostim
Therapeutic Area: Infections and Infectious Diseases Brand Name: Molgradex
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Lead Product(s) : Molgramostim
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company has decided to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF).
Brand Name : Molgradex
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 03, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?